Form 4: C4 Therapeutics Director Kenneth Anderson Acquires Shares in Lieu of Cash Compensation

Director Kenneth Anderson acquired 3,074 shares of C4 Therapeutics common stock at $3.66 per share in lieu of cash compensation, according to a Form 4 filing.

Summary

• Kenneth Anderson, a director of C4 Therapeutics, acquired 3,074 shares of common stock on January 2, 2025.
• The shares were issued as compensation for services as a non-employee director, in lieu of cash.
• The price per share was $3.66, based on the closing market price on the transaction date.
• Following the transaction, Anderson directly owns 119,768 shares.
• Anderson also has indirect ownership through spousal holdings and grantor retained annuity trusts.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a standard transaction related to director compensation. The director's decision to take stock instead of cash could be seen as a slightly positive signal.

Positives

• Director's confidence in the company is demonstrated by electing to receive shares instead of cash compensation.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Director compensation in the form of stock is a common practice among publicly traded companies, aligning the interests of directors with those of shareholders.
• The specific amount and terms of stock compensation vary widely based on company size, industry, and individual director agreements.
• Comparing C4 Therapeutics' director compensation policy to those of similar biotech companies would provide a more detailed benchmark.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates